Summary
Abbott Laboratories reported solid financial results for the third quarter and the first nine months of 2000, demonstrating year-over-year growth in both net sales and earnings. Net sales increased by 5.8% to $3.318 billion for the quarter and 3.4% to $10.041 billion for the nine-month period. Diluted earnings per share saw a significant increase of 40.0% in the third quarter and 14.0% for the nine months, reflecting operational improvements and the absence of certain charges incurred in the prior year related to an FDA consent decree. The company's performance was driven by strong growth in its Pharmaceutical and Hospital product segments, along with robust international sales. However, the Diagnostics segment experienced a decline, largely attributed to the ongoing impact of the FDA consent decree, which restricts the manufacturing and distribution of certain products and is estimated to negatively impact sales by up to $250 million for the full year 2000. Despite these challenges, Abbott maintained its strong liquidity position and favorable credit ratings, underscoring its financial stability.
Key Highlights
- 1Net sales increased by 5.8% to $3.318 billion for the third quarter ended September 30, 2000, compared to $3.137 billion in the prior year.
- 2Diluted earnings per share rose by 40.0% to $0.42 for the third quarter of 2000, compared to $0.30 in the same period of 1999.
- 3For the nine months ended September 30, 2000, net sales grew by 3.4% to $10.041 billion, and diluted EPS increased by 14.0% to $1.30.
- 4The company reported a $139 million gain from the sale of its agricultural products business in January 2000.
- 5Abbott maintained a strong liquidity position with $878 million in cash and cash equivalents and $1.505 billion in unused domestic lines of credit.
- 6The Diagnostics segment experienced a sales decline due to the ongoing impact of an FDA consent decree, which is expected to affect full-year sales by up to $250 million.